Source: Annual Congress 2006 - Hypoxic and inflammatory insults to the pulmonary circulation.
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Samarzija, M. Jakopovic, G. Redzepi, E. Zuljevic, B. Sever, S. Plestina, N. Miculinic, F. Pavicic (Zagreb, Croatia). Efficacy of a 12 months oral sildenafil treatment in patients with severe pulmonary hypertension. Eur Respir J 2006; 28: Suppl. 50, 3832

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with PAH Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Sildenafil for treatment of associated pulmonary hypertension in patients with severe COVID-19 pneumonia. Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Evaluation of tiotropium rotacaps once daily in patients with chronic obstructive pulmonary disease over 4 weeks Source: Eur Respir J 2005; 26: Suppl. 49, 289s Year: 2005 A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006 Survival with first-line bosentan in patients with primary pulmonary hypertension. Source: Eur Respir J 2005; 25: 942 Year: 2005 Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary circulation Year: 2007 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Long-term treatment of pulmonary hypertension with aerosolized iloprost Source: Eur Respir J 2001; 17: 8-13 Year: 2001 Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009